Hoth TherapeuticsHOTH
About: Hoth Therapeutics Inc is a development-stage biopharmaceutical company. It is focused on targeted therapeutics for patients suffering from conditions such as atopic dermatitis, also known as eczema, chronic wounds, psoriasis, asthma, and acne. The company owns the BioLexa Platform which combines an FDA-approved zinc chelator with one or more approved antibiotics in a topical dosage form to address unchecked eczema flare-ups.
Employees: 3
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
50% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 2
50% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 2
9% more funds holding
Funds holding: 11 [Q2] → 12 (+1) [Q3]
1.85% less ownership
Funds ownership: 6.69% [Q2] → 4.84% (-1.85%) [Q3]
10% less capital invested
Capital invested by funds: $327K [Q2] → $293K (-$33.3K) [Q3]
Research analyst outlook
6 Wall Street Analysts provided 1 year price targets over the past 3 months
6 analyst ratings
D. Boral Capital Jason Kolbert 23% 1-year accuracy 25 / 107 met price target | 525%upside $5 | Buy Maintained | 13 Nov 2024 |
HC Wainwright & Co. Raghuram Selvaraju 41% 1-year accuracy 126 / 309 met price target | 400%upside $4 | Buy Reiterated | 4 Nov 2024 |
HC Wainwright & Co. Raghuram Selvaraju 41% 1-year accuracy 126 / 309 met price target | 400%upside $4 | Buy Reiterated | 16 Oct 2024 |
Benchmark Bruce Jackson 36% 1-year accuracy 19 / 53 met price target | 275%upside $3 | Speculative Buy Reiterated | 11 Oct 2024 |
EF Hutton Jason Kolbert 23% 1-year accuracy 25 / 107 met price target | 525%upside $5 | Buy Maintained | 5 Sept 2024 |
